Neurocrine Biosciences IncNASDAQ:NBIX
- LAST PRICE139.6600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 139.6600
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NBIX |
|---|---|---|
| 09:32 ET | 2329 | 140.25 |
| 09:34 ET | 300 | 139.986 |
| 09:36 ET | 300 | 139.01 |
| 09:38 ET | 510 | 139.09 |
| 09:39 ET | 300 | 139 |
| 09:41 ET | 600 | 139.12 |
| 09:48 ET | 200 | 139.345 |
| 09:50 ET | 2200 | 139.8 |
| 09:52 ET | 300 | 140.06 |
| 09:54 ET | 100 | 140.075 |
| 09:56 ET | 100 | 140.1755 |
| 09:57 ET | 300 | 140.1 |
| 09:59 ET | 200 | 140.055 |
| 10:01 ET | 200 | 140.23 |
| 10:03 ET | 2704 | 139.385 |
| 10:06 ET | 200 | 139.39 |
| 10:08 ET | 400 | 139.67 |
| 10:10 ET | 100 | 139.76 |
| 10:12 ET | 100 | 139.99 |
| 10:14 ET | 320 | 140.19 |
| 10:15 ET | 700 | 139.77 |
| 10:17 ET | 200 | 139.79 |
| 10:19 ET | 200 | 139.88 |
| 10:21 ET | 210 | 140.035 |
| 10:24 ET | 644 | 139.81 |
| 10:26 ET | 800 | 139.64 |
| 10:30 ET | 100 | 139.64 |
| 10:32 ET | 282 | 139.793 |
| 10:33 ET | 900 | 139.66 |
| 10:35 ET | 400 | 139.7 |
| 10:37 ET | 500 | 139.87 |
| 10:39 ET | 2396 | 139.84 |
| 10:42 ET | 700 | 139.675 |
| 10:48 ET | 300 | 139.81 |
| 10:50 ET | 800 | 139.74 |
| 10:51 ET | 800 | 139.8825 |
| 10:53 ET | 300 | 140.1 |
| 10:55 ET | 300 | 140.13 |
| 10:57 ET | 3541 | 140.18 |
| 11:00 ET | 494 | 140.46 |
| 11:02 ET | 1798 | 140.29 |
| 11:04 ET | 300 | 140.27 |
| 11:08 ET | 1300 | 140.32 |
| 11:09 ET | 400 | 140.265 |
| 11:11 ET | 600 | 140.2353 |
| 11:13 ET | 300 | 140.31 |
| 11:15 ET | 100 | 140.345 |
| 11:18 ET | 900 | 140.29 |
| 11:20 ET | 500 | 140.16 |
| 11:22 ET | 1800 | 139.875 |
| 11:24 ET | 200 | 140.095 |
| 11:26 ET | 600 | 140.04 |
| 11:27 ET | 460 | 140.165 |
| 11:29 ET | 910 | 140.015 |
| 11:31 ET | 200 | 140.07 |
| 11:33 ET | 800 | 139.71 |
| 11:36 ET | 500 | 139.58 |
| 11:38 ET | 455 | 139.48 |
| 11:40 ET | 200 | 139.64 |
| 11:42 ET | 600 | 139.43 |
| 11:44 ET | 200 | 139.53 |
| 11:45 ET | 500 | 139.37 |
| 11:47 ET | 100 | 139.36 |
| 11:49 ET | 1200 | 139.56 |
| 11:51 ET | 400 | 139.6 |
| 11:58 ET | 3121 | 139.77 |
| 12:00 ET | 500 | 139.62 |
| 12:03 ET | 200 | 139.55 |
| 12:05 ET | 200 | 139.57 |
| 12:07 ET | 1163 | 139.67 |
| 12:09 ET | 200 | 139.66 |
| 12:12 ET | 800 | 139.74 |
| 12:14 ET | 900 | 139.81 |
| 12:16 ET | 100 | 139.835 |
| 12:18 ET | 400 | 139.765 |
| 12:20 ET | 100 | 139.78 |
| 12:21 ET | 380 | 139.865 |
| 12:23 ET | 100 | 139.76 |
| 12:25 ET | 100 | 139.86 |
| 12:27 ET | 2065 | 139.53 |
| 12:30 ET | 800 | 139.46 |
| 12:32 ET | 564 | 139.58 |
| 12:36 ET | 778 | 139.59 |
| 12:38 ET | 100 | 139.725 |
| 12:39 ET | 692 | 139.685 |
| 12:43 ET | 600 | 139.85 |
| 12:45 ET | 481 | 139.67 |
| 12:48 ET | 907 | 139.72 |
| 12:50 ET | 100 | 139.6 |
| 12:52 ET | 200 | 139.64 |
| 12:56 ET | 100 | 139.78 |
| 12:57 ET | 126 | 139.735 |
| 12:59 ET | 1043 | 139.82 |
| 01:01 ET | 800 | 139.93 |
| 01:03 ET | 1038 | 140.12 |
| 01:06 ET | 700 | 140.01 |
| 01:10 ET | 200 | 140.125 |
| 01:12 ET | 2466 | 139.86 |
| 01:15 ET | 100 | 140 |
| 01:17 ET | 1100 | 140 |
| 01:19 ET | 300 | 140.015 |
| 01:21 ET | 200 | 140.03 |
| 01:24 ET | 1316 | 139.95 |
| 01:26 ET | 361 | 139.87 |
| 01:28 ET | 100 | 139.995 |
| 01:30 ET | 200 | 140.02 |
| 01:32 ET | 1050 | 139.995 |
| 01:33 ET | 200 | 139.94 |
| 01:35 ET | 900 | 140.24 |
| 01:37 ET | 808 | 140.23 |
| 01:42 ET | 101 | 140.185 |
| 01:44 ET | 1984 | 140.17 |
| 01:46 ET | 100 | 140.155 |
| 01:48 ET | 100 | 140.23 |
| 01:50 ET | 1350 | 140.17 |
| 01:51 ET | 1216 | 140.17 |
| 01:55 ET | 300 | 140.11 |
| 01:57 ET | 600 | 140.09 |
| 02:00 ET | 1007 | 139.99 |
| 02:02 ET | 100 | 139.9375 |
| 02:04 ET | 485 | 140.005 |
| 02:08 ET | 300 | 140 |
| 02:09 ET | 300 | 140.1 |
| 02:11 ET | 2291 | 139.86 |
| 02:13 ET | 100 | 139.835 |
| 02:15 ET | 2875 | 139.8 |
| 02:18 ET | 100 | 139.67 |
| 02:20 ET | 1006 | 139.785 |
| 02:22 ET | 100 | 139.8 |
| 02:24 ET | 832 | 139.77 |
| 02:26 ET | 1900 | 139.84 |
| 02:27 ET | 1094 | 139.885 |
| 02:29 ET | 2700 | 139.81 |
| 02:31 ET | 100 | 139.77 |
| 02:36 ET | 616 | 139.75 |
| 02:38 ET | 473 | 139.8 |
| 02:40 ET | 1100 | 139.695 |
| 02:42 ET | 1300 | 139.535 |
| 02:45 ET | 2309 | 139.52 |
| 02:47 ET | 100 | 139.595 |
| 02:49 ET | 4260 | 139.695 |
| 02:51 ET | 3089 | 139.79 |
| 02:54 ET | 1300 | 139.88 |
| 02:56 ET | 2360 | 139.88 |
| 02:58 ET | 2500 | 139.825 |
| 03:00 ET | 1804 | 139.87 |
| 03:03 ET | 100 | 139.975 |
| 03:05 ET | 100 | 139.96 |
| 03:09 ET | 2250 | 139.86 |
| 03:12 ET | 2200 | 139.725 |
| 03:14 ET | 900 | 139.85 |
| 03:16 ET | 300 | 139.83 |
| 03:20 ET | 2496 | 139.73 |
| 03:21 ET | 1947 | 139.5 |
| 03:23 ET | 1200 | 139.44 |
| 03:25 ET | 500 | 139.64 |
| 03:27 ET | 1000 | 139.48 |
| 03:30 ET | 861 | 139.34 |
| 03:32 ET | 500 | 139.405 |
| 03:34 ET | 200 | 139.43 |
| 03:36 ET | 4563 | 139.53 |
| 03:38 ET | 300 | 139.49 |
| 03:39 ET | 2829 | 139.415 |
| 03:41 ET | 2156 | 139.41 |
| 03:43 ET | 2425 | 139.45 |
| 03:45 ET | 2115 | 139.41 |
| 03:48 ET | 1100 | 139.455 |
| 03:50 ET | 4471 | 139.41 |
| 03:52 ET | 5622 | 139.465 |
| 03:54 ET | 4944 | 139.49 |
| 03:56 ET | 8841 | 139.43 |
| 03:57 ET | 11074 | 139.485 |
| 03:59 ET | 99208 | 139.66 |
Yesterday
Neurocrine Biosciences Presents CAHtalyst(TM) Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024, from 17 hours ago by Dow Jones
17 hours ago by Dow JonesNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults, from 18 hours ago by Dow Jones
18 hours ago by Dow Jones
May 8, 2024
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults, from 8:30AM ET on Wednesday May 08, 2024 by Dow Jones
8:30AM ET on Wednesday May 08, 2024 by Dow Jones
May 7, 2024
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference, from 4:15PM ET on Tuesday May 07, 2024 by Dow Jones
4:15PM ET on Tuesday May 07, 2024 by Dow JonesNeurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst(TM) Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024, from 8:30AM ET on Tuesday May 07, 2024 by Dow Jones
8:30AM ET on Tuesday May 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neurocrine Biosciences Inc | 14.0B | 38.4x | +62.04% |
Medpace Holdings Inc | 12.0B | 40.7x | +35.10% |
Biomarin Pharmaceutical Inc | 15.5B | 77.4x | --- |
Qiagen NV | 9.5B | 28.6x | +12.66% |
United Therapeutics Corp | 11.6B | 12.6x | +8.22% |
Sarepta Therapeutics Inc | 12.5B | 1,660.6x | --- |
Company Information
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).
Contact Information
- Headquarters
- 6027 EDGEWOOD BEND COURTSAN DIEGO, CA, United States 92130
- Phone
- 858-617-7600
- Fax
- 858-617-7602
Executives
- Non-Executive Independent Chairman of the Board
- William Rastetter
- Chief Executive Officer, Director
- Kevin Gorman
- Chief Financial Officer
- Matthew Abernethy
- Chief Human Resource Officer
- Julie Cooke
- Chief Scientific Officer
- Jude Onyia
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.1B |
|---|---|
Revenue (TTM) | $2.0B |
Shares Outstanding | 100.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.36 |
EPS | $3.64 |
Book Value | $22.61 |
P/E Ratio | 38.4x |
Price/Sales (TTM) | 7.1 |
Price/Cash Flow (TTM) | 35.8x |
Operating Margin | 23.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
